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The World Health Organization’s (WHO’s) 2030 road map for neglected tropical diseases (NTDs) emphasizes the importance of strength-
ened, institutionalized “post-elimination” surveillance. The required shift from disease-siloed, campaign-based programming to routine, 
integrated surveillance and response activities presents epidemiological, logistical, and financial challenges, yet practical guidance on im-
plementation is lacking. Nationally representative survey programs, such as demographic and health surveys (DHS), may offer a platform 
for the integration of NTD surveillance within national health systems and health information systems. Here, we describe characteristics of 
DHS and other surveys conducted within the WHO Africa region in terms of frequency, target populations, and sample types and discuss 
applicability for post-validation and post-elimination surveillance. Maximizing utility depends not only on the availability of improved 
diagnostics but also on better understanding of the spatial and temporal dynamics of transmission at low prevalence. To this end, we out-
line priorities for obtaining additional data to better characterize optimal post-elimination surveillance platforms.
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Ensuring effective post-intervention and elimination surveillance 
is a challenge that faces all neglected tropical diseases (NTDs) 
programs [1, 2]. As successful preventive chemotherapy (PC) 
and intensified disease management (IDM) interventions drive 
down infection prevalence and/or disease incidence, remaining 
affected individuals become more unevenly distributed across 
space and populations. Outlier areas and population groups be-
come more prominent for transmission and potentially harder to 
find, and larger samples over broader areas are required to con-
firm trends [2]. Consequently, determining the optimal design of 
stand-alone and integrated surveillance approaches both during 
program implementation and prior to verification of elimination 
has been an urgent priority [3]. Once programs reach elimination 
targets, however, there is little consensus or guidance on how best 
to maintain effective surveillance [4]. This operational gap risks 
leaving countries vulnerable to undetected recrudescence, which 
could lead to resurgence of infections and undo years of progress 
in NTD control.
Due to the pressing need to provide clear guidance to 
programs that are reaching elimination targets, we now need 
greater focus on post-elimination surveillance: how can we 
identify recrudescence in a timely way and at a reasonable cost? 
What scale of sampling, at what frequency, and among which 
sentinel populations are required? Here, we discuss these is-
sues and outline key requirements for post-elimination surveil-
lance platforms and their relevance across the range of NTDs 
currently flagged by the World Health Organization (WHO) 
for elimination, either in terms of transmission or as a public 
health problem, by 2030. This review is restricted to the WHO 
Africa region because this is the region with the highest burden 
of NTDs and represents a case study that illustrates the ques-
tions that need to be answered for all countries with active NTD 
programs approaching or anticipating elimination.
What Does Elimination Mean in the Context of NTDs?
Individual targets for NTD eradication and elimination as a 
public health problem have been hugely influential in driving 
progress; committing governments, donors, and health 
workers to focus on these neglected diseases; and facilitating 
unprecedented levels of support from pharmaceutical com-
panies. As part of its road map for reducing the burden of 
NTDs, the WHO has identified eradication or elimination 
targets for 13 diseases, although for most this does not mean 
reducing prevalence or incidence to zero [1]. Only 2 diseases 
(yaws and dracunculiasis) are targeted for eradication, and 
an additional 3 (human African trypanosomiasis gambiense, 
leprosy, and onchocerciasis) for interruption of transmis-
sion. The remaining 8 are targeted for elimination as a public 
health problem, the definition of which varies substantially 
between diseases, from achieving zero or very low case fatality 
(rabies and visceral leishmaniasis) to reducing prevalence of 
moderate and heavy infection (soil transmitted helminthiasis 
[STH] and schistosomiasis). For additional details of these 
goals, see Supplementary Table 1.
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In most instances, NTD programs, be they for PC or IDM dis-
eases, have not been integrated within routine activities performed 
by primary care structures but instead run as parallel interventions, 
often with the support of a range of partners and stakeholders. To 
ensure sustainability and contribute to health system strength-
ening, there are now increasing calls to replace these vertical struc-
tures with routine, integrated surveillance of NTDs in endemic 
countries [5–7]. Opportunities for integration and mainstreaming 
and the ongoing relative importance of passive and active surveil-
lance systems, will depend not only on stated elimination goals 
but also on key disease characteristics, particularly the pathogen 
life cycle and transmission route, the proportion of infections that 
result in severe disease, the relevance of asymptomatic cases for 
transmission, the availability of diagnostic tools for asymptomatic 
infections, and the public health response that would be triggered 
by the detection of an infectious case.
Broadly, for NTDs controlled through individual case de-
tection and management (IDM NTDs, including leprosy and 
rabies), incredibly low population prevalence post-elimination 
make stand-alone surveys unworkable. Instead, post-validation 
surveillance will remain dependent on reports triggered by 
symptomatic case presentation, with the public health response 
centered on treatment of the individual case along with other 
investigations, such as contact tracing, source identification, 
and/or community sensitization [1, 8–10]. This becomes in-
creasingly challenging as countries achieve elimination targets, 
as has been demonstrated for leprosy and yaws, both of which 
have had long-standing elimination and eradication goals. In 
many instances, these diseases are no longer seen as a public 
health priority, resource allocations have been reduced and ex-
pertise lost, cases have become increasingly clustered among 
marginalized populations with low accessibility, and progress 
has stagnated [1, 2].
A recent history of renewed investment and strengthened 
public–private partnerships [3], combined with calls for en-
hanced integration [4], have regalvanized IDM programs glob-
ally. Task-shifting of case identification and management closer 
to affected communities, coupled with training of and moti-
vation for healthcare workers, strengthened reporting, better 
diagnostics and treatments, and innovative active case finding 
strategies, are all likely to play pivotal roles if elimination 
goals are to be successfully achieved. Crucially, however, once 
reached, these efforts (and the investments required to achieve 
them) will need to be broadly sustained to prevent reemergence.
For PC-NTDs, opportunities for post-elimination surveil-
lance may vary depending on the disease in question. For STH 
and schistosomiasis, achievement of elimination as a public 
health problem does not mean the end of PC interventions; as 
a result, resources and infrastructure for stand-alone surveil-
lance (eg, through school-based surveys) will potentially be 
safeguarded for the post-elimination era. In contrast, PC inter-
ventions for lymphatic filariasis, onchocerciasis, and trachoma 
stop after verification of elimination; as a result, surveillance 
to detect resurgence is more likely to require systems external 
to existing NTD programs. For these diseases, transmission is 
driven by cases of asymptomatic and subclinical infections [5, 
6]; consequently, in post-elimination settings, an active surveil-
lance system to identify these infections would be required. The 
detection of an infectious case would trigger a public health re-
sponse that might include mass treatment of the community 
or wider area in which the case was identified [4], but specific 
management of the individual infected would not be necessary. 
The primary health system may detect some additional infec-
tions [7], but its main role would be in providing management 
and rehabilitation services to patients affected by the sequelae of 
past infections and in monitoring the numbers of these patients 
(which are also indicators for the verification of elimination of 
diseases such as lymphatic filariasis and trachoma [11]).
Toward Practical Integrated Surveillance
In many NTD-endemic countries, passive surveillance systems 
already face issues of underresourcing, low representativeness 
due to uneven levels of access and availability of health serv-
ices, and low sensitivity of clinical diagnosis, which will worsen 
as clinical expertise is lost due to reduced disease incidence. 
To ensure effective post-elimination surveillance of NTDs, it 
will be essential that the NTD community remains focused on 
strengthening the primary healthcare system and improving ac-
cess to care. However, large-scale, active surveillance platforms 
will additionally be required for the surveillance of PC-NTDs.
Nationally representative survey programs such as dem-
ographic and health surveys (DHS) may offer an appropriate 
platform for active surveillance, and already play an impor-
tant role in epidemiological monitoring of infectious diseases 
including malaria and human immunodeficiency virus (HIV) 
[12]. These programs are typically conducted by in-country in-
stitutions with external technical and financial assistance and 
are characterized by enhanced data infrastructure and well-
organized testing capabilities. To assess the feasibility and utility 
of leveraging nationally representative survey programs for 
NTD post-elimination surveillance, we reviewed key character-
istics of the major population-based survey programs in Africa.
Surveys were identified using information from the Global 
Health Data Exchange [13]. We considered all representative 
health-monitoring survey programs currently taking blood 
samples ( “blood surveys”), chosen because these already have 
an infrastructure available for the collection and analysis of bio-
markers, and all DHS regardless of sample collection (as the lar-
gest institution conducting nationally-representative surveys), 
with an assumption that biomarker collection may be an addi-
tional module that could be integrated into future surveys.
We identified 185 blood surveys conducted between 1997 
and 2019 (surveys ongoing at the time of analysis were ex-
cluded) in the WHO African region. These included DHS, 
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AIDS, and malaria indicator surveys (AIS and MIS) and special 
surveys (all conducted through the DHS program by USAID 
[14]); multiple indicator cluster surveys (MICS, conducted 
by UNICEF [15]); population-based HIV impact assessments 
(conducted by ICAP [16]); and STEPwise chronic disease risk 
factor surveillance surveys (conducted by WHO [17]). The in-
cluded surveys represented 45 out of 47 countries in the WHO 
African region. There were no surveys recorded for Guinea-
Bissau or South Sudan.
For the second dataset, we included 227 DHS conducted be-
tween 1986 and 2020. Survey types included AIS, DHS, MIS, 
MICS, and special surveys and included 42 countries in the 
WHO African region. There were no surveys recorded for 
Algeria, Guinea-Bissau, Mauritius, Seychelles, or South Sudan.
Survey Design and Frequency
Impact assessment surveys for monitoring the status of 
PC-NTD control programs prior to achieving elimination are 
usually designed as community- or school-based cluster sur-
veys representative at the level of the implementation unit 
(typically an administrative or health district) or an evaluation 
unit representing a group of implementation units with sim-
ilar transmission characteristics [18–20]. Rather than measure 
prevalence to a given level of precision, they are usually in-
tended to classify units as above or below a target prevalence 
threshold. For diseases including onchocerciasis and schisto-
somiasis, purposive sampling is recommended in areas of ex-
pected high transmission [8], which is intended to increase 
the likelihood of identifying foci of infection, but at the cost of 
survey representativeness.
In contrast, DHS-style surveys are generally designed to be 
representative at the national level, the residence level (urban–
rural), and the regional level (departments, states), with enu-
meration areas selected systematically within strata with 
probability proportional to size. The indicators they measure re-
quire smaller sample sizes for representativeness at these levels 
than do surveys for NTDs [9], suggesting that data collected 
through this platform may be too sparse to detect foci of recru-
descence of public health importance. However, they may be 
able to provide a platform for surveillance if certain adaptations 
to increase precision can be integrated.
Adaptations to conventional survey design might include 
additional adaptive or snowball sampling and spatial oversam-
pling in areas predicted to be at higher risk of transmission 
using geostatistical models [10]. Adaptive sampling may include 
testing of household or community members of identified cases 
[21], which is appropriate for NTD surveillance since many 
of these diseases show strong spatial clustering. Model-based 
geostatistical (MBG) analysis frameworks allow for incorpora-
tion of spatial correlation and environmental covariates and can 
lead to significant predictive gains. Notably, MBG approaches 
are increasingly applied to improve inference from malaria data 
collected through MIS platforms [22, 23]. Additional data on 
the extent of spatial heterogeneity observed at different spatial 
scales in very low transmission settings for NTDs are essential 
if we are to fully evaluate this utility further.
A second consideration is the periodicity of sampling. 
Although the optimal survey frequency for post-elimination 
NTD surveillance (balancing timely detection of recrudescence 
with surveys costs) remains to be determined and is an impor-
tant research priority, recommended post-MDA surveillance 
for STH currently uses 3-year surveys and that for LF involves 
2- to 3-year surveys in the immediate post-validation era. We 
therefore assumed that programs that conducted at least 3 sur-
veys in the past 10 years would provide the minimum frequency 
required to detect recrudescence of NTDs at a level of public 
health importance and examined the frequency of DHS against 
this threshold.
Figure 1 provides a summary of DHS conducted by country, 
with the number of surveys performed in each country in the 
previous 10 years provided as a measure of survey frequency. 
Twenty-five countries undertook 3 or more DHS in the past 
10 years, and 14 had only 1 or no surveys over this time. The 
mapped data in Figure 1 illustrate the large area of central 
Africa in which countries currently under mass drug admin-
istration (MDA) or partly under post-MDA surveillance for 
lymphatic filariasis, used as an illustrative example, have survey 
rounds of insufficient frequency for adequate post-elimination 
surveillance. This demonstrates that there cannot be sole re-
liance on DHS for effective surveillance without a substantial 
increase in survey frequency in all countries at risk of recru-
descence. However, additional research, including multiyear 
cross-sectional studies in post-elimination settings, and math-
ematical modeling will be required to determine the minimum 
frequency of post-elimination surveillance to detect recrudes-
cence at levels of public health importance for different NTDs 
in the longer term.
Age Ranges and Sentinel Populations
Appropriate target populations for post-elimination NTD sur-
veillance depend mainly on the age groups or populations most 
at risk, although these may vary across different transmission 
settings [24]. An additional consideration is that detection of 
antibodies for an infection in any age group born since verifica-
tion of elimination indicates post-elimination transmission and 
would be a key criterion for public health action.
For schistosomiasis and STH, target product profiles (TPPs) 
of diagnostics for post-elimination surveillance have recom-
mended targeting children aged 6–14  years [25], while those 
for trachoma surveillance recommended focusing on children 
aged 1–5 years, although evidence from modeling studies has 
suggested a target population of children aged 1–9 years, which 
is in line with guidelines for monitoring of programmatic im-
plementation [26]. For lymphatic filariasis, post-elimination 
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surveys have generally targeted wider age ranges, although 
children aged <2  years have rarely been sampled in the past, 
and sometimes activities have been focused on children [4]. 
Mathematical modeling of onchocerciasis transmission indi-
cates that the most appropriate target age group depends on age-
specific exposure patterns in different contexts: surveillance of 
children aged 0–9 years is recommended in areas where expo-
sure increases rapidly from birth, while surveillance of children 
aged 5–14 years is recommended where exposure increases at a 
slower rate [24].
Figure 2 shows the representation of males and females by 
age in surveys that collect blood samples conducted in the 
WHO African region, illustrating the underrepresentation of 
school-age children in all nationally representative surveys in 
the region. This is because they principally test for HIV, malaria 
and anemia, for which school-age children are not a sentinel 
population. When testing for HIV, DHS and AIS surveys gener-
ally sample women of reproductive age (15–49 years) and males 
aged 15–59 years. For anemia, women of reproductive age and 
children aged 6–59 months are sampled, while for malaria only 
children aged 6–59 months are included. For STH and schisto-
somiasis, the highest burden of infection is among school-age 
children; as a result, survey coverage of this age group would 
have to be expanded if surveys such as the DHS were to become 
viable platforms for post-elimination surveillance. Sentinel 
populations for post-elimination surveillance of other NTDs 
must be confirmed to ensure that survey sample collection in-
cludes appropriate age groups.
Biomarkers
At present, surveillance for NTDs is dependent on a dis-
parate range of biomarkers, most not well suited for post-
elimination surveillance. For example, in areas endemic for 
Wuchereria bancrofti filariasis, WHO recommends the Alere 
Filariasis Test Strip (FTS), which measures circulating filarial 
antigen in human blood. However, the FTS is cross-reactive 
Figure 1. Frequency of DHS by country in the WHO Africa region. Dots indicate years in which a DHS was conducted. The size of each dot reflects the number of years 
out of the previous 10 in which a DHS took place. The number of surveys conducted in 2008–2018 is shown in brackets. Countries with more than 3 surveys in 2008–2018 
(ie, surveys at least roughly every 3 years) are highlighted in bold. African countries are colored according to the number of DHS surveys conducted in 2008–2018. Survey 
frequency is compared with status of LF control in each country, as defined by surveillance and MDA status using data from the Expanded Special Project for Elimination of 
Neglected Tropical Diseases. Abbreviations: CAR, Central African Republic; DHS, demographic and health survey; DRC, Democratic Republic of Congo; LF, lymphatic filariasis; 
MDA, mass drug administration; STP, Sao Tome and Principe; WHO, World Health Organization.
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with Loa loa antigens [27], which limits its utility for post-
elimination surveillance in (previously) coendemic set-
tings. STH and schistosomiasis are routinely detected using 
microscopy-based diagnostic tools that count the number of 
parasite eggs excreted in urine or stool. However, the low sen-
sitivity of these methods when infection intensities are very 
low means they are considered inadequate for elimination 
surveillance [28].
Diagnostics, however, are likely to keep improving as 
programs progress, and TPPs that specify the minimum and 
ideal characteristics for diagnostics for post-elimination sur-
veillance are already published for schistosomiasis [29], STH, 
and trachoma and are in development for lymphatic filari-
asis [25, 29]. According to published TPPs, acceptable post-
elimination surveillance diagnostics for schistosomiasis, STH, 
and trachoma would be based on detection of antibodies in 
finger-stick blood samples that could be used with minimal or 
no infrastructure [25].
Considering a scenario where future diagnostics measure 
blood or sera-based biomarkers for all NTDs included within 
the surveillance platform, it should be noted that dried blood 
spots (DBS) were collected by 101 surveys (55.0%) and whole 
blood by just 18 (10.8%) of identified blood surveys (Figure 
3). The relatively high coverage of DBS is encouraging, as this 
would facilitate the application of seroepidemiological methods 
that have been previously applied to NTDs including trachoma, 
lymphatic filariasis, schistosomiasis, and onchocerciasis in re-
search settings [26, 30–33]. The development and validation 
of multiplex serological assays further increase the operational 
feasibility of serological techniques in surveillance by enabling 
Figure 2. Representation of males and females by age in surveys that collected blood samples conducted in the African region.
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measurement of a broad range of responses with high repeata-
bility from limited blood samples [34].
WAYS FORWARD AND CONCLUSIONS
Crucially, ongoing post-elimination NTD surveillance must be 
at a low cost to maintain government and donor commitment 
to diseases that will no longer be regarded as public health is-
sues. NTD surveillance integrated within existing systems will 
maintain low costs of monitoring and strengthen current in-
frastructure, using existing passive or active surveillance sys-
tems, or a combination of the 2. Lessons can be learned from 
other disease areas. Countries that have successfully eliminated 
malaria, for example, have typically relied on a combination of 
both passive and active case detection, with staff dedicated to 
surveillance and integrated response mechanisms [11], coupled 
with integration within DHS platforms.
Inclusion in DHS or future alternative representative sur-
veys will require adjustments to both the DHS and the NTD 
programs. In order to better understand these adjustments and 
provide a clearer characterization of optimal post-elimination 
surveillance, we offer some considerations for future work. First, 
an increase in the number of epidemiological studies at fine spa-
tial scale conducted within countries that previously had NTDs 
as a public health problem and in areas very close to elimina-
tion thresholds is needed. These studies would provide greater 
insight into the extent and importance of spatial heterogeneity 
at low prevalence settings. Second, increasing the number of 
samples collected from individuals outside the usual age groups 
(eg, during impact assessment surveys) would help to ensure 
that age infection profiles are better defined and that appro-
priate sentinel populations identified. Third, to test mathemat-
ical transmission models of recrudescence and to understand 
the population-level seroreversion rate needed for serological 
surveillance approaches, longitudinal or repeat cross-sectional 
studies conducted several years apart are needed.
Existing large-scale survey platforms offer enormous 
potential for integrated surveillance, and so it is perhaps 
Figure 3. Number of large-scale surveys ever conducted by country for the WHO Africa region. Left side shows the number of all surveys that collected blood samples by 
sample type. Right side shows all demographic and health surveys ever conducted, whether they collected blood samples and sample type, where relevant. Where multiple 
samples were taken, surveys using WBS were categorized as WBS, those using a mixture of DBS and RDT were categorized as DBS, and those using RDT and other types of 
tests were categorized as RDT. Abbreviations: CAR, Central African Republic; DBS, dry blood spot; DRC, Democratic Republic of Congo; NS, not stated; RDT, rapid diagnostic 
test; STP, Sao Tome and Principe; WBS, whole blood sample. 
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unsurprising that they are already overloaded with questions. 
Given the increasing potential of integrated serosurveillance, 
it is likely that in time blood spots will likewise become over-
loaded with requests. To provide sufficient justification for 
inclusion of NTDs, it will be essential that we improve our 
operational research evidence base, including target product 
profiles for new diagnostics, to take full advantage of these 
possibilities.
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